Ryan D. Ross

Ryan D. Ross

Auto-generated profile, based on publicly available information

Ryan D. Ross

Department of Anatomy and Cell Biology, Rush University Medical Center , Chicago, Illinois

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Current Osteoporosis Reports
Verified
Journal Article
Closed access
PDF file
KAKyle D. Anderson
Kyle D. Anderson
FKFrank C. Ko
Frank C. Ko
AVAmarjit S. Virdi
Amarjit S. Virdi
DSD. Rick Sumner
D. Rick Sumner
RRRyan D. Ross
Ryan D. Ross

10 December 2019 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
KCKelsey A Carpenter
Kelsey A Carpenter
RRRyan D Ross
Ryan D Ross
X-linked hypophosphatemia (XLH), caused by a loss-of-function mutation in the phosphate regulating gene with homology to endopeptidase located on the X chromosome (PHEX), is the most common form of vitamin D-resistant rickets. Loss of functional PHEX results in elevated fibroblast growth factor 23 (FGF23) levels, impaired phosphate reabsorption, and inhibited skeletal mineralization. Sclerostin, a protein produced primarily in osteocytes, suppresses bone formation by antagonizing Wnt signaling and is reported to be elevated in XLH patients. This study used the Hyp mouse model to investigate sclerostin's role in the pathophysiology of XLH by evaluating the use of a monoclonal antibody to sclerostin in a mouse model of XLH, the Hyp mouse. Male and female wild-type and Hyp littermates were injected with 25 mg/kg of vehicle or sclerostin antibody (Scl-Ab) twice weekly, beginning at 4 weeks of age and euthanized at 8 weeks of age. Scl-Ab treatment increased serum phosphate levels and suppressed circulating levels of intact FGF23 in treated wild-type and Hyp mice of both sexes. Cortical area, trabecular bone volume fraction (BV/TV), metaphyseal apparent density, and the peak load increased with Scl-Ab treatment in both sexes. This short-term treatment study suggests that Scl-Ab treatment can effectively improve some of the pathologies associated with XLH, including normalization of phosphate, and that sclerostin may play a role in regulating FGF23 and phosphate metabolism in XLH. © 2019 American Society for Bone and Mineral Research.

8 February 2018 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
RRRyan D Ross
Ryan D Ross
RSRaj C Shah
Raj C Shah
SLSue Leurgans
Sue Leurgans
TBTeodoro Bottiglieri
Teodoro Bottiglieri
RWRobert S Wilson
Robert S Wilson
DSDale Rick Sumner
Dale Rick Sumner
Osteoporosis and Alzheimer’s disease are common diseases of aging that would seem to be unrelated, but may be linked through the influence of bone-derived signals on brain function. The aim of the current study is to investigate the relationship between circulating levels of bone-related biomarkers and cognition. The population included 103 community-dwelling older individuals with memory concerns but without cognitive impairment. A global cognition summary measure was collected at baseline and 6, 12, and 18 months post-enrollment by converting raw scores from 19 cognitive function tests to z-scores and averaging. Baseline plasma concentrations of bone-related biomarkers, including undercarboxylated, carboxylated, and total osteocalcin, parathyroid hormone, C-terminal telopeptide of collagen 1 (CTX-1), procollagen type 1 amino-terminal propeptide, osteoprotegrin, osteopontin, Dickkopf WNT signaling pathway inhibitor 1 (Dkk1), sclerostin, and amyloid β peptides (Aβ40 and Aβ42), were measured. Using sex, age, and education-adjusted mixed-effects models, we found that baseline levels of TNF-related apoptosis-inducing ligand (TRAIL; p < .001), Dkk1 (p = .014), and CTX-1 (p = .046) were related to the annual rate of change of global cognition over the 18 month follow-up. In cognitive domain-specific analysis, baseline TRAIL was found to be positively related to the annual rate of change in episodic (p < .001) and working memory (p = .016), and baseline Dkk1 was positively related to semantic memory (p = .027) and negatively related to working memory (p = .016). These results further confirm the link between bone and brain health and suggest that circulating levels of bone-related biomarkers may have diagnostic potential to predict worsening cognition.

20 June 2022 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
AOArnold Z. Olali
Arnold Z. Olali
KCKelsey A. Carpenter
Kelsey A. Carpenter
MMMaria Myers
Maria Myers
ASAnjali Sharma
Anjali Sharma
MYMichael T. Yin
Michael T. Yin
RRRyan D. Ross
Ryan D. Ross

1 October 2022 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
RRRyan D. Ross
Ryan D. Ross
AOArnold Z. Olali
Arnold Z. Olali
QSQiuhu Shi
Qiuhu Shi
DHDonald R. Hoover
Donald R. Hoover
ASAnjali Sharma
Anjali Sharma
LRLeah H. Rubin
Leah H. Rubin
Introduction: Bone loss and cognitive impairment are common in women living with HIV (WLWH) and are exacerbated by menopause. Bone-derived undercarboxylated osteocalcin (ucOCN) and sclerostin appear to influence cognition. The current study investigated whether the circulating levels of these 2 proteins are associated with cognition in midlife WLWH and demographically similar HIV seronegative women. Methods: Plasma samples from women enrolled in a musculoskeletal substudy within the Women's Interagency HIV Study were used to measure ucOCN and sclerostin. A neuropsychological (NP) test battery assessing executive function, processing speed, attention/working memory, learning, memory, verbal fluency, and motor function was administered within 6 months of musculoskeletal enrollment and every 2 years after (1–4 follow-up visits per participant). A series of generalized estimating equations were conducted to examine the association between biomarkers and NP performance at the initial assessment and over time in the total sample and in WLWH only. Primary predictors included biomarkers, time, and biomarker by time interactions. If the interaction terms were not significant, models were re-run without interactions. Results: Neither biomarker predicted changes in NP performance over time in the total sample or in WLWH. ucOCN was positively associated with executive function in the total sample and in WLWH and with motor skills in WLWH. ucOCN was negatively associated with attention/working memory in the total sample. There were no significant associations between sclerostin and NP performance. Conclusion: The current study suggests an association between bone-derived ucOCN and cognition in women with and without HIV infection.

16 September 2021 in Bone
Verified
Journal Article
Closed access
KCKelsey A. Carpenter
Kelsey A. Carpenter
RDReid Davison
Reid Davison
SSShruti Shakthivel
Shruti Shakthivel
KAKyle D. Anderson
Kyle D. Anderson
FKFrank C. Ko
Frank C. Ko
RRRyan D. Ross
Ryan D. Ross